Chapter 79 Drug Update: Toceranib

  1. Carlsten KS et al: Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors, J Vet Intern Med 26:135, 2012. PUBMED Abstract
  2. Chon E et al: Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumor-bearing dogs (excluding mast cell tumors): a phase I dose-finding study, Vet Comp Oncol 10:184, 2012. Epub March 21, 2011. PUBMED Abstract
  3. London CA et al: Unpublished data.
  4. London CA et al: Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies, Clin Cancer Res 9:2755, 2003. PUBMED Abstract
  5. London CA et al: Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision, Clin Cancer Res 15:3856, 2009. PUBMED Abstract
  6. London C et al: Preliminary evidence for biologic activity of toceranib phosphate (Palladia®) in solid tumours, Vet Comp Oncol 10:194, 2012. Epub June 1, 2011.
  7. Papaetis GS, Syrigos KN: Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies, Biodrugs 23:377, 2009. PUBMED Abstract
  8. Robat C et al: Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study, Vet Comp Oncol 10:174, 2012. Epub January 31, 2011. PUBMED Abstract